argenx SE (0QW0.IL)
| Previous close | 340.90 |
| Open | 336.00 |
| Bid | 319.60 x N/A |
| Ask | 353.20 x N/A |
| Day's range | 333.50 - 336.40 |
| 52-week range | 257.00 - 405.10 |
| Volume | |
| Avg. volume | 25,307 |
| Market cap | 18.672B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.48 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual Genera
- Globe Newswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT
- Globe Newswire
argenx Announces Planned Transition of Chief Operating Officer
Karen Massey appointed as Chief Operating Officer, effective March 13, 2023Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023. Ms. Massey will succeed Keith Woods, who will remain at a
